Dendreon Corp fka DNDNQ

[ocyanblue]

<4. Changing the 9902b protocol to make Cox the primary endpoint supports the contention in item #3 above and makes 9902b the real pivotal study, in my view. (I.e., DNDN learned ex post facto that Cox gave a good result in 9902a and hence they are testing this Cox endpoint prospectively in 9902b. This is how things are supposed to be done.)>

This is a truly neat insight. I didn't know that Dendreon does research in biostatistics and is trying to get the FDA approval to sell a that to cure prostate cancer. I always thought that the endpoint for 9902b was survival. This Cox endpoint is something else. I guess we learn something new every day. Thanks Dew.